Regenerative Medicine

The Next Evolution of Medical Treatments

The field of regenerative medicine offers the promise of curing certain diseases, rather than merely treating symptoms. The U.S. Department of Health and Human Services has called regenerative medicine the “next evolution of medical treatments because it works to replace damaged or diseased organs or restore organ function with cell therapy.” Scientists at Wake Forest Institute for Regenerative Medicine are leaders in this field and were first in the world to engineer laboratory-grown organs that were successfully implanted into humans

About Wake Forest Institute for Regenerative Medicine

Today, the interdisciplinary team at Wake Forest Institute for Regenerative Medicine is working to engineer more than 40 different replacement tissues and organs and to develop healing cell therapies.

Partner with our faculty to develop, support and commercialize novel regenerative medicine technologies. Whether the institute’s multidisciplinary team is executing a project from concept or bringing fresh ideas to an existing effort, our experts bring proven experience to the effort.

The institute is internationally recognized for its cutting-edge translational programs in:

  • Biomaterials
  • Enabling technologies
  • Organoregenesis
  • Stem cell therapies
  • Tissue engineering

Research in these areas is at various stages in the development pipeline, including preclinical and clinical.


In addition to basic science research collaborations, the institute has an active program in preclinical research, having successfully brought several technologies from the bench through the regulatory process. Our scientists have expertise in a variety of animal models, including nonhuman primates, and are developing a body-on-a-chip system to take the place of animals in drug testing.


An on-site dedicated good manufacturing facility (GTP and GMP compliant) enables the development of replacement tissues and organs and the expansion of cells for therapy under guidelines of the U.S. Food and Drug Administration. This facility, combined with a network of clinicians who consult with the institute, supports Phase I and Phase II trials, ensuring a reproducible, proven product.

Technology Licensing

Opportunities to license intellectual property for commercialization are available.

Interested in Regenerative Medicine Research?

Contact us and learn how our leaders in regenerative medicine can contribute to your research with cutting-edge technologies and techniques.
  • This field is for validation purposes and should be left unchanged.